MediSieve CEO Dr George Frodsham attended the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Boston, joining researchers, clinicians, biotechnology companies and industry leaders from across the global cell and gene therapy community.

The meeting provided an opportunity to reconnect with existing collaborators, meet potential future partners and follow the latest scientific developments in AAV gene therapy. A particular focus for MediSieve was the continuing challenge posed by anti-AAV neutralising antibodies, which can prevent patients from receiving AAV-based therapies and remain a major barrier to future redosing.

George also took part in discussions through the AAV Seropositivity Group, which brings together researchers and industry participants working to better understand and address immune responses to these therapies.

About MediSieve  

MediSieve is a London-based start-up developing Magnetic Blood Filtration, a platform designed to selectively remove clinically relevant targets from the bloodstream. The technology combines target-specific therapeutic Magnetic Beads with an extracorporeal Capture System. During treatment, the Magnetic Beads are introduced into the extracorporeal blood circuit, where they mix with the patient’s blood and bind to their targets. The Capture System then magnetically removes the Beads and bound targets before the blood is returned to the patient. 

MediSieve’s lead application is focused on depleting anti-AAV neutralising antibodies (NAbs), which can exclude patients from receiving life-changing AAV gene therapy and prevent redosing. By removing anti-AAV NAbs prior to AAV administration, MediSieve aims to expand patient eligibility and create a potential pathway to future redosing. 

Beyond AAV gene therapy, Magnetic Blood Filtration is being developed as a broader platform that can be adapted to remove other clinically relevant circulating targets, either as a direct therapeutic approach or to enable other treatments. MediSieve is a spin-out from University College London and develops its technology in the White City Innovation District in West London.